Budget Process
OHS committee considering dumbing down successful PCMH standards
Among other troubling plans, the Office of Health Strategy’s Primary Care Subgroup is considering four options to certify high-performing primary care practices for higher levels of reimbursement. The committee is deciding how to double spending on primary care while simultaneously capping healthcare cost growth. At their meeting this week, the committee of mainly primary care…
Read MoreOP-ED | Controversial New Alzheimer’s Drug Could Break the Bank
Alzheimer’s disease affects six million Americans, stealing memories years before it takes lives. Aduhelm, the first drug intended to treat the Alzheimer’s disease process rather than symptoms, was highly anticipated by patients and families. But it has disappointed on many levels. It isn’t clear that it actually helps patients and troubling side effects are common.…
Read MoreBOOK CLUB — The Right Price: A Value-Based Prescription for Drug Costs
For your summer reading. The Right Price: A Value-Based Prescription for Drug Costs offers the best explanation I’ve found of how drug costs are set, and how they should be. Using real-life patient stories, the authors give a balanced and comprehensive look at fair and reasonable pricing for a product that epitomizes market failure. The…
Read MoreJAMA highlights CT bill to limit extreme drug price increases
A recent JAMA article highlights bills to reduce drug price increases across states, including Connecticut’s bill. The bills call for clawing back 80% of drug price increases over inflation plus 2% — a healthy profit that many industries would happily welcome. Other states also considering bills include Massachusetts, Maine, Washington, and Hawaii; more are expected…
Read MoreCTNJ: OP-ED | Drug Affordability Requires Limits On Price Gouging
Jay Gironimi has cystic fibrosis and he is grateful for the drugs that help him live. But he disagrees with the Epilepsy Foundation’s opinion piece that defends extreme drug price hikes. “While the drugs are saving lives today, the profit margins are slowly tanking the entire US healthcare system.” Read more
Read MoreResponse: Lobbyist uses seniors and people with disabilities to protect drug company profits
Reading William Smith’s CT Mirror opinion, I was worried that my state had passed draconian laws that were harming the health of seniors and people with disabilities. Thankfully, that isn’t the case. Our anti-discrimination laws are still in place and functioning. . . . True discrimination against seniors and people with disabilities happens every day…
Read MoreCTNJ Opinion: Remember Public Health’s Value After COVID Is Gone
The COVID-19 pandemic has focused a bright light on the weakness of the U.S. public health system. Countries with strong public health systems fared much better in controlling the virus’ spread. America used to have a strong public health system. From 1900 to 2000, life expectancy rose by 30 years. Contrary to public opinion, it…
Read MoreGovernor’s consultant report recommendations for Medicaid savings are baseless
It’s not in the headlines but the biggest source of potential savings, $200 million, proposed by the Governor’s controversial report from Boston Consulting Group (BCG) to save money in state government to is to go back to failed Medicaid financial risk models. There are two problems with the proposal. First, the financial risk models don’t…
Read MoreHUSKY COVID update – new enrollments lag, lots of money to providers, and telehealth is very popular
At Friday’s Medicaid Council meeting, we learned that while new HUSKY applications recovered last fall from its drop last spring, they fell again sharply this January and February. The reasons for the volatility during a serious recession are unclear. DSS focused on how HUSKY has responded to the COVID pandemic. Now covering over a million…
Read MoreCTNJ Op-Ed – Drug Innovation Argument Cuts Both Ways
In his recent op-ed, John Burkhardt of Pfizer misses important points when he asserts that the governor’s proposed tax on excessive prescription drug price increases will harm innovation and jobs in Connecticut. He ignores that rising drug prices are making health insurance unaffordable. Overpriced drugs inhibit other innovation and job growth across Connecticut’s economy. He…
Read More